Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer
The purpose of this study is to assess the effectiveness and safety profile of AiyiÂ®(Tegafur Gimeracil Oteracil Potassium Capsule, TS-1) as a second line therapy in Chinese female patients with advanced metastatic breast cancer.
Breast Cancer
DRUG: Tegafur Gimeracil Oteracil Potassium Capsule
Progression-free survival, Up to 2 years
Clinical response rate, Assessed by RECIST v1.1 criteria., Every six weeks|Adverse events, Subjects will be followed from date of enrollment until the date of last visit, anticipated up to 2 years
Tegafur Gimeracil Oteracil Potassium Capsule is a novel oral derivative of the 5-fluorouracil(5-FU) prodrug tegafur combined with two modulators. Recent clinical trial has reported the promising effect of Tegafur Gimeracil Oteracil Potassium Capsule in metastatic breast cancer. The innovative drug, S-1, has obtained the approval of treatment of advanced breast cancer in Japan, meanwhile, Generic drug is only approved for the indication of gastric cancer in China mainland by Chinese authority, SFDA, and no Chinese clinical study data of TS-1 in breast cancer so far.